Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy

References

• Balducci L, Hardy C H. Anemia of aging: a model of cancer-related anemia. Cancer Control JHLMCC 1998; 5(suppl)17–21
   PubMedGoogle Scholar
• Chatta G S, Price T H, Allen R C, Dale D C. Effects of “in vivo” recombinant methionyl human granulocyte colony stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994; 84: 2923–2929
   PubMed Web of Science ®Google Scholar
• Lipschitz D A. Age-related decline in hemopoietic reserve capacity. Semin Oncol 1995; 22(suppl 1)3–6
   PubMed Web of Science ®Google Scholar
• Moscinski L C. Hemopoiesis and aging. Comprehensive geriatric oncology, L Balducci, G H Lyman, W B Ershler. Harwood Academic Publisher, Amsterdam 1999; 399–412
   Google Scholar
• Rlee M A, Segal G M, Bagby G C. The hematopietic microenvironment in the elderly: defects in IL-1-induced CSF expression in vitro. Exp Hematol 1989; 17: 952–956
   PubMed Web of Science ®Google Scholar
• Shank W J, Balducci L. Recombinant hemopoietic growth factors: comparative response in younger and older subjects. J Am Geriatric Soc 1992; 40: 151–154
   PubMed Web of Science ®Google Scholar
• Armitage J O, Potter J F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. J Am Geriatr Soc 1984; 32: 269–273
   PubMed Web of Science ®Google Scholar
• Bastion Y, Blai J Y, Divine M, Brice P, Bordessoule D, Sebban C, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment and survival. A Groupe d'Etude des Lymphomes de l'Adulte Study on 453 patients older than 69 years. J Clin Oncol 1997; 15: 2945–2953
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Pavone E, Storti S, Moretti L, Fattori P P, Guardigni L, et al. Randomized trial with or without granulocyte colony-stimulalting factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 89: 3974–3978
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94: 33–38
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, et al. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 2002; 13: 1364–1369
   PubMed Web of Science ®Google Scholar
• Bertini M, Freilone R, Vitolo U, Botto B, Pizzuti M, Gavarotti P, et al. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: Feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma 1994; 22: 483–493
   Web of Science ®Google Scholar
• Gomez H, Mas L, Casanova L, Pen D L, Santillana S, Valdivia S, et al. Eldely patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998; 16: 2352–2358
   PubMed Web of Science ®Google Scholar
• Greil R. Prognosis and management strategies of lymphatic neoplasia in the elderly. Oncology 1998; 55: 189–217
   PubMed Web of Science ®Google Scholar
• Meyer R M, Browman G P, Samosh M L, Benger A M, Bryant-Lukosius D, Wilson W E, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 2386–2393
   PubMed Web of Science ®Google Scholar
• O'Reilly S E, Connors J M, Howdle S, Hoskins P, Klasa R, Klimo P, et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: Results of a phase II study of P/DOCE chemotherapy. J Clin Oncol 1993; 11: 2250–2257
   PubMed Web of Science ®Google Scholar
• Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP vs CNOP chemotherapy. J Clin Oncol 1995; 13: 2530–2539
   PubMed Web of Science ®Google Scholar
• Tirelli U, Errante D, Van Glabbeke M, Teodorovic I, Kluin-Nelemans J C, Thomas J, et al. CHOP is the standard regimen in patients _ 70 years of age with intermediate grade and high grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative study. J Clin Oncol 1998; 16: 27–34
   PubMed Web of Science ®Google Scholar
• Schiffer C A. Hematopoietic growth factors as adjuncts to the treatment of acute myelogenous leukemia. Blood 1996; 88: 3675–3685
   PubMed Web of Science ®Google Scholar
• Cleary J F. Cancer pain in the elderly. Comprehensive geriatric oncology, L Balducci, G H Lyman, W B Ershler. Harwood Academic Publisher, Amsterdam 1998; 753–764
   Google Scholar
• Cleeland C S, Demetri G D, Glapsy J. Identifying hemoglobin levels for optimal Quality of Life. Results of an incremental analysis. Proceedings of the American Society of Clinical Oncology 1999; 16: 574a
   Google Scholar
• Demetri G D, Kris M, Wade J, Degos L, Cella D, Procrit Study Group. Quality of life benefit in chemotherapy patients treated with epoietin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998; 16: 3412–3425
   PubMed Web of Science ®Google Scholar
• Gabrilove J L, Einhorn L H, Livingston R B. Once weekly dosing of epoietin alfa is similar to three-times weekly dosing in icreasing hemoglobin and quality of life. Proceedings of the American Society of Clinical Oncology 1999; 16: 574
   Google Scholar
• Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoietin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218–1234
   PubMed Web of Science ®Google Scholar
• Spivak J L. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994; 21: 3–8
   PubMed Web of Science ®Google Scholar
• Miller C B, Jones R J, Piantadosi S, Abeloff M D, Spivak J L. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689–1692
   PubMed Web of Science ®Google Scholar
• Zucker S. Anemia in cancer. Cancer Invest 1985; 3: 249–260
   PubMed Web of Science ®Google Scholar
• Jelkmann W, Page H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1992; 50: 301–308
   PubMed Web of Science ®Google Scholar
• Faquin W C, Schneider T J, Goldberg M A. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987–1994
   PubMed Web of Science ®Google Scholar
• Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard E M, et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998; 9: 1109–1115
   PubMed Web of Science ®Google Scholar
• Morrow T J, Volpe S, Gupta S, Tannous R E, Fridman M. Anemia of cancer in intermediate-grade non-Hodgkin's lymphoma. South Med J 2002; 95: 889–896
   PubMed Web of Science ®Google Scholar
• Carbone P P, Kaplan H S, Musshoff K. Report of the Committee on Hodgkin's Disease Staging Classifications. Cancer Res 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Cox D R. Regression models and life-tables (with discussion). J Royal Statistical Society 1972; 34: 187–220
   Google Scholar
• SAS Institute Inc. SAS/STAT Software: changes and enhancements through release 6.11. SAS Institute Inc, Scary, NC 1996
   Google Scholar
• Gallagher C J, Gregory W M, Jones A E, Stansfeld A G, Richards M A, Dhaliwal H S, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989; 7: 1018–1026
   PubMed Web of Science ®Google Scholar
• Cowan R A, Jones M, Harris M, Steward W P, Radford J A, Wagstaff J, et al. Prognostic factors in high and intermediate-grade non-Hodgkin's lymphoma. Br J Cancer 1989; 50: 276–282
   Web of Science ®Google Scholar
• Dixon D O, Neilan B, Jones S E, Lipschitz D A, Miller T P, Grozea P N, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group Experience. J Clin Oncol 1986; 4: 295–305
   PubMed Web of Science ®Google Scholar
• Conlan M G, Armitage J O, Bast M, Weisenburger D D. Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis. Cancer 1991; 67: 1389–1395
   PubMed Web of Science ®Google Scholar
• Romaguera J E, McLaughlin P, North L, Dixon D, Silvermintz K B, Garnsey L A, et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 1991; 9: 762–769
   PubMed Web of Science ®Google Scholar
• Leonard R CF, Hayward R L, Prescott R J, Wang J X. The identification of discrete prognostic groups in low-grade non-Hodgkin's lymphoma. Ann Oncol 1991; 2: 655–662
   PubMed Web of Science ®Google Scholar
• Bremnes R M, Bremnes Y, Donnem T. High-grade non-Hodgkin's lymphoma treated in northern Norway. Treatment, outcome and prognostic factors. Acta Oncol 1999; 38: 117–124
   PubMed Web of Science ®Google Scholar
• Steward W P, Crowther D, McWilliam L J, Jones J M, Deakin D P, Todd I D, et al. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin” lymphoma: a randomized prospective study with an assessment of prognostic factors. Cancer 1988; 61: 441–447
   PubMed Web of Science ®Google Scholar
• Morel P, Lepage E, Brice P, Dupriez B, D'Agay M F, Fenaux P, et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 1992; 7: 1078–1085
   Google Scholar